Nistatin

Quick links to important sections

Nistatin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nistatin

Property Description
Active ingredient Nystatin
Pharmacological class Antifungal Agent, Polyene Macrolide Antibiotic
Form Tablet, Suspension, Cream, Ointment, Powder
Common use Management of localized fungal overgrowth
Origin Natural product (derived from Streptomyces noursei)

Nistatin: Identity and Classification as a Highly Selective Antifungal

Nistatin, officially known by the INN Nystatin, is a specific type of antifungal agent that is firmly established within the polyene macrolide antibiotic pharmacological class. This compound is historically and chemically recognized as a natural product, being one of the most effective antifungals synthesized by the bacterium Streptomyces noursei. Its primary differentiation factor from typical antibiotics is its narrow spectrum of activity, which is strictly limited to fighting fungal pathogens, particularly Candida species. The effectiveness of Nystatin in managing localized fungal infections is clinically recognized and supported by systematic reviews published in medical literature.

Composition, Forms, and Focused Local Action

Nistatin is primarily a single-ingredient product, containing Nystatin as the sole active compound, which is prepared with an inert base suited to its intended local use. Nystatin is uniquely formulated for administration via oral, topical, and intravaginal routes, a direct consequence of its most significant characteristic: its systemic absorption is minimal following oral or topical delivery. This property is key, ensuring the therapeutic action is concentrated locally at the site of infection (e.g., the mouth or gut) while minimizing systemic exposure. The availability of forms such as oral suspension or topical cream highlights its position as a flexible, localized agent for mucocutaneous and gastrointestinal fungal management.

General Therapeutic Role and Mechanism Principle

Nistatin’s general therapeutic purpose is to control and prevent the growth of superficial fungal overgrowth, providing the benefit of clearing the infection. This therapeutic effect is achieved through a specific mechanism principle where the Nystatin molecule actively targets and binds to ergosterol, a sterol that is crucial and unique to the fungal cell membrane. This binding disrupts the membrane's integrity, forming pores that lead to the leakage of the cell's contents. This action is fungicidal or fungistatic, resulting in the effective suppression of the localized fungal population.

Regulatory References

  1. Nystatin label (NIH DailyMed)

What side effects are possible with Nistatin?

Possible Side Effects and Safety Information

Nistatin is generally considered well-tolerated due to its minimal systemic absorption from the gastrointestinal tract and skin. Adverse reactions are primarily localized and minor.

Classification Common Side Effects Rare/Serious Reactions
Gastrointestinal (Oral Forms) Diarrhea, nausea, vomiting, stomach upset or pain, bloating. N/A
Dermatologic/Local Mouth or throat irritation, rash, itching, burning, and irritation at the application site (topical forms). Severe skin reactions, including Stevens-Johnson syndrome; Anaphylaxis (serious allergic reaction); Urticaria (hives), facial swelling.
Other N/A Fast heart rate (tachycardia), muscle pain (myalgia).

Key Safety Considerations

  • Contraindications: Nistatin is contraindicated in individuals with a known hypersensitivity to any of its components.
  • Systemic Use: This medication is not indicated for the treatment of systemic (internal) fungal infections, as it is not significantly absorbed into the bloodstream.
  • Local Irritation: If irritation or sensitization develops during treatment, the medication should be discontinued.
  • Pregnancy and Lactation: Oral and topical nistatin products are typically assigned a Pregnancy Category C by the FDA, meaning that it should be used only if the potential benefit justifies the potential risk. It is not known if Nistatin is excreted in human milk; caution is advised when administered to a nursing mother.
  • Dose-Related Effects: Oral doses in excess of five million units daily have been reported to cause only mild gastrointestinal distress, such as nausea and upset stomach.

The overall safety profile is dominated by local effects, consistent with its mechanism of action, with systemic risks being limited to extremely rare but serious hypersensitivity reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Nystatin overdose is closely tied to its minimal systemic absorption from the gastrointestinal tract.


Documented Manifestations and Outcomes

Classification Official Regulatory Statement
Documented Symptoms Oral doses in excess of five million units daily have caused nausea and gastrointestinal upset. Potential signs also include vomiting and stomach pain/bloating.
Systemic Risk Overdosage or accidental ingestion is stated to cause no systemic toxicity. There are no reports of serious toxic effects or superinfections resulting from overdosage.

Required Emergency Actions

Management is officially described as symptomatic and supportive, and no specific antidote is documented in regulatory labeling. The level of required response is determined by the severity of the clinical presentation.

Immediate Action Mandated:

  • If overdose is suspected, seek professional assistance or contact a Poison Control Center immediately.
  • Emergency services must be contacted if the individual exhibits severe, life-threatening symptoms, such as collapse, a seizure, trouble breathing, or inability to be awakened, as stated in patient information.

Therapeutic Uses of Nistatin

What Nystatin Treats: Main Uses and Benefits

Nystatin is applied across domains where additional symptomatic support is needed, particularly for conditions characterized by localized yeast overgrowth, such as mucocutaneous candidiasis and oral thrush. The medication helps address symptom clusters that may become intense or disruptive, including soreness, a burning sensation, and the presence of white, irritating patches. This therapeutic approach contributes to easing the overall symptom load and may assist with maintaining functional stability during symptomatic phases.

The medication is commonly used to help with non-systemic fungal issues in other areas, such as cutaneous candidiasis on the skin and gastrointestinal candidiasis in the digestive tract. It is relevant for managing symptom clusters that may become intense or disruptive, such as itching, redness, and irritation in moist body areas. Nystatin is considered relevant for patient groups, including infants and immunocompromised individuals, that experience acute or recurrent candidiasis.

“The use of this medicine is relevant in contexts marked by increased discomfort or tension associated with localized fungal symptoms.”

Quick Fact: Relief for Mucosal Discomfort Nystatin may assist with managing symptoms related to physical discomfort associated with irritative states in the mouth and on the skin.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Nistatin

Nistatin eligibility is defined by regulatory bodies based on population type, hypersensitivity, and the drug's limited absorption. Use is strictly contraindicated for individuals with a known history of hypersensitivity to Nystatin or any of the inactive ingredients in the specific formulation.


Official Eligibility Constraints

Population Group Regulatory Status
Systemic Fungal Infections Contraindicated (Must not be used due to negligible absorption).
Adults and Children Generally Established. Use is permitted for all age groups, including neonates and infants, for localized infections.
Young Children Restricted Use for lozenges/tablets (oral suspension is preferred for children under 5 years for safety of administration).
Pregnancy Conditional Use. Recommended only if clearly needed or if the potential benefit outweighs the potential risk (FDA Category C).
Lactation Caution is advised, as it is not known if Nystatin is excreted in human milk.

Due to its minimal systemic absorption, no specific dose adjustments are required for patients with hepatic or renal impairment, implying standard eligibility for localized use. Official labeling notes that clinical data on topical use in individuals aged 65 and older is insufficient to determine differential response.

What should I know about interactions with other medicines?

Nystatin Interactions with Other Medicines and Products

Nystatin's interaction profile is fundamentally shaped by its negligible systemic absorption when administered orally or topically. Regulatory documents from health authorities confirm that Nystatin generally achieves no detectable concentration in the bloodstream. Consequently, the drug presents virtually no risk for traditional systemic pharmacokinetic interactions, which involve liver enzymes (e.g., CYP) or drug transporters that might alter the blood levels of co-administered medications.


The documented interactions are primarily related to local effects at the site of administration.

Documented Local Interaction Constraints

Interaction Type Interacting Substance/Product Practical Implication
Local Degradation Allogeneic Cultured Keratinocytes/Fibroblasts Avoid co-administration due to Nystatin's degradative action on the product.
Pharmacodynamic Antagonism Clotrimazole (or similar antifungals) Potential reduction in the efficacy of the co-administered antifungal agent.

There are no official regulatory statements requiring the separation of Nystatin doses from food or alcohol, nor are there any stated interactions with herbal products or dietary supplements. Furthermore, the regulatory labeling does not identify specific interaction modifications necessary for patients with impaired hepatic or renal function.

Mechanism of Action

How Nystatin Works

The action of Nystatin is defined by its selective, physical disruption of the fungal cell membrane, which acts as a direct binder to ergosterol. Ergosterol is a sterol molecule unique to the fungal plasma membrane, providing the mechanistic basis for selective toxicity by restricting the drug’s physical effects primarily to fungal cells.

The binding cascade leads Nystatin to function as an ionophore that creates stable transmembrane pores (channels) in the fungal cell wall. This pore formation causes the rapid, uncontrolled efflux of essential ions, specifically Potassium ( K^+). This immediate loss of K^+ and other contents compromises the cell's electrochemical gradient and osmotic balance, culminating in rapid fungal cell lysis. This swift physiological disruption results in the suppression of the localized fungal population.

Dosage and Administration Information

Nystatin is utilized with an emphasis on its localized activity through specific administration techniques and duration requirements. It is administered via the oral route as a suspension or tablet, and the topical route as a cream, ointment, or powder. Due to its negligible systemic absorption, Nystatin is not indicated for the treatment of systemic fungal infections.

The typical administration frequency is three or four times daily, depending on the formulation. The standard dose for adult oral suspension is generally in the range of 400,000 to 600,000 units per dose, while administration for infants requires a lower, specific dose, such as 200,000 units four times a day.

The protocol for the oral suspension requires specific steps to ensure maximum contact time with the infection site. The dose must be retained in the mouth for as long as possible before swallowing. Standard protocols involve dividing the total volume, with half placed in each side of the mouth. Administration is typically advised after meals or feeding; subsequent food or drink should be avoided for approximately 30 minutes post-dose.

Regarding course duration, treatment must be continued for a minimum of at least 48 hours after symptoms have completely subsided to prevent recurrence, or until healing is complete for topical forms.

Recent Clinical Evidence

Research evidence / Overview of studies for Nistatin


Evidence for Use in Oral Candidiasis (Oral Thrush)

Nystatin was studied for oral candidiasis—often called oral thrush—in research exploring short-term symptom changes. The evidence base includes numerous Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies have primarily focused on measuring the clearance of the fungal organism from the mouth (mycological cure) and the resolution of physical signs, focusing on patient-reported outcomes describing perceived discomfort. Research was evaluated in immunocompetent infants and children, as well as general adults who were included based on specific risk factors.

Research highlights changes measured during the study period, with findings indicate data show patterns related to both mycological outcomes and patient-reported measures. However, reported outcomes were mostly short-term, typically covering the few weeks of the treatment protocols studied.


Evidence for Use in Denture Stomatitis

Nystatin was evaluated in trials assessing short-term or episodic symptom patterns related to denture stomatitis—inflammation often found under dentures and associated with Candida. The research includes RCTs and systematic reviews that focused on the evaluation of Nystatin, including the use of its pastille form. Studies monitored outcomes linked to inflammatory or irritative states, specifically looking for the resolution of inflammation and soreness, as well as confirming the clearance of the fungus from the mouth and the denture material.

Studies report how symptoms evolved in the observed populations, where outcomes related to inflammatory states were monitored over several weeks. Research provides insight into short-term changes, but these study results reflect the specific conditions under which they were conducted, with many trials comparing Nystatin to inactive controls.


Evidence in Special Populations

Specific research has examined how Nystatin was evaluated in certain patient groups where symptoms may become more noticeable or disruptive.

In the case of Very Low Birth Weight (VLBW) preterm infants, a group where outcomes related to systemic imbalance are a major concern, the data show patterns related to this group that were observed across multiple studies. Studies observed responses over defined time intervals and data show patterns related to fungal colonization that was observed in some studies compared to control groups.

For immunocompromised adult patients (e.g., patients with cancer or organ transplants), research has explored its use during periods of increased symptom activity. However, data show patterns related to preventative use in this specific group are often inconsistent, and the certainty remains low regarding its impact on outcomes like fungal infection incidence or mortality.


Evidence Gaps and Areas of Uncertainty

Findings help contextualize how patients reported their experience, but research also highlights several areas where further data are still emerging and certainty remains low.

One key limitation is that evidence quality varies across studies, with many older trials having small sample sizes or other design weaknesses. Furthermore, comparative evidence is lacking in some areas, meaning Nystatin has often been studied against placebo or no treatment, but its performance against all currently available active comparators is not uniformly characterized across all indications. The research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about the patterns observed in the studies.

Key Studies & References

  1. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis
  2. Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin (Cochrane Review)
  3. Therapeutic Role of Nystatin Added to Tissue Conditioners for Treating Denture-Induced Stomatitis: A Systematic Review
  4. Nystatin: MedlinePlus Drug Information (Authoritative source on approved uses)

Frequently Asked Questions (FAQ)

Common questions about Nistatin (FAQ)


Q: What types of fungal infections is Nistatin primarily used to treat?

Official prescribing information indicates that Nistatin is used to treat infections caused by Candida species. These indications include candidiasis of the oral cavity (oral thrush), non-esophageal infections of the gastrointestinal tract (tablets), and fungal infections of the skin or mucous membranes (topical forms).


Q: Is Nistatin considered an antibiotic or a specific type of antifungal medication?

According to official regulatory documents, Nistatin is technically classified as a polyene antimycotic antibiotic. This means it is a specialized medication with demonstrated activity against a wide variety of yeasts and yeast-like fungi. It does not have significant activity against bacteria, protozoa, or viruses.


Q: Why is Nistatin liquid suspension prescribed instead of a pill for oral thrush?

The oral suspension is prescribed for infections in the mouth because it allows for localized treatment. The administration protocol for the liquid formulation specifies that it is designed to be swished and held in the mouth before swallowing. This method ensures maximum contact time with the infection site, while tablets are formulated for infections lower in the gastrointestinal tract.


Q: Is Nistatin effective against other infections besides those caused by the Candida yeast species?

Official product information states that Nistatin exhibits activity against a wide variety of yeasts and yeast-like fungi. However, the medication is primarily indicated for use in infections specifically caused by Candida albicans and other susceptible Candida species.


Q: Is Nistatin used as a preventative medication in certain patient populations?

Clinical summaries and patient information suggest that Nistatin can be used in a preventative manner (prophylactically) in certain situations. This may include using a specific dose to prevent the onset of oral candidiasis in patients identified as being at high risk for fungal infection.


Q: How long does Nistatin typically take to start working for a skin infection?

Based on patient information summaries, people using Nistatin topical forms may start to notice improvement in their symptoms after about two days of consistent use. The official course duration for topical treatment is typically until the infection is completely healed, which is intended to prevent recurrence.


Q: What should a patient do if the infection does not improve after one week of Nistatin treatment?

Official warnings and precautions state that if there is a lack of therapeutic response, a re-evaluation of the diagnosis is needed. This may involve repeating appropriate microbiological studies, such as cultures or KOH smears, to confirm the diagnosis or rule out other pathogens, prior to any change in the course of therapy.


Q: Can the Nistatin liquid be mixed with food or juice to help with the taste?

Patient administration instructions specify that the Nistatin oral suspension should not be mixed with any food, water, or other drinks. The medicine is intended to be used alone to maximize its localized contact with the infection site, and subsequent food or drink should be avoided for a short period after administration.


Q: Is the proper use of Nistatin affected by wearing dentures?

For individuals with oral candidiasis who wear full or partial dentures, proper use may involve an additional step. Clinical summaries note that soaking the dentures in the oral suspension may be necessary to help eliminate the fungus from the denture material, which is a common source of reinfection.


Q: Does Nistatin pose a risk of damage or stress to the liver?

Due to Nistatin’s negligible systemic absorption following oral or topical administration, it presents a very low risk for systemic effects. Official documents do not list liver damage or stress as a common side effect or specific precaution, which is consistent with the drug’s minimal systemic absorption.


Q: Are there any special precautions needed if Nistatin is used on a baby's diaper rash?

When the medication is applied topically in the diaper area of infants, patient information indicates a special precaution. Covering the treated skin with tight-fitting diapers or plastic pants should be avoided, as this may hinder the healing process or potentially increase skin absorption.


Q: Can Nistatin cream be safely used on open or raw areas of the skin?

The product label states that the medication should be discontinued if local irritation or sensitization develops during treatment. Patient care summaries indicate that providers may need to be informed if a patient has large areas of burned or damaged skin, suggesting a need for a clinical assessment prior to use on raw areas.


Q: Is Nistatin still effective if a dose is missed during the treatment course?

Official dosing instructions provide a standard protocol for a missed dose. The standard protocol for a missed dose is to take it as soon as it is remembered, unless it is almost time for the next scheduled dose. It is advised to never take double or extra doses to make up for a missed one.


Q: What does research indicate about Nistatin resistance in fungi over time?

According to the official prescribing information, studies indicate that resistance to Nistatin generally does not develop in the body (in vivo) during a typical course of treatment. This is a characteristic of the medication's specific mechanism of action.


Q: Does Nistatin remain effective if it is stored incorrectly (e.g., if the liquid freezes)?

Official storage instructions for the oral suspension and other forms include an explicit warning to avoid freezing. This is because freezing the product may affect its stability or physical consistency, which could compromise the medication’s intended effectiveness.


Q: Can the topical form of Nistatin be used for a long period of time?

The labeled use for topical Nistatin is for the duration needed until the infection is completely healed. Regulatory documents note that Nistatin is generally well tolerated, even with prolonged use for oral and gastrointestinal indications, suggesting a favorable local safety profile.


Q: Why are patients sometimes advised to use loose clothing or cotton fabrics while using Nistatin cream?

Patient instructions related to using Nistatin cream for skin infections often advise wearing loose-fitting, cotton clothing. This advice is provided to help keep the treated area dry and reduce the conditions that allow the fungus to thrive, thereby assisting in the prevention of irritation and reinfection.


Q: Is Nistatin safe for use by elderly patients, given their potential for other health conditions?

Official sources note that there is generally no specific clinical information comparing the use of Nistatin in elderly patients versus younger age groups. However, official documents report no specific warnings or restrictions for use in geriatric patients.


Q: Does Nistatin liquid need to be shaken well before each use?

Patient administration instructions specify that the Nistatin suspension bottle should be shaken well before each use. This step is necessary to ensure that the medication is evenly mixed within the liquid base before the dose is measured.


Q: What types of laboratory tests are sometimes ordered to monitor a patient's response to Nistatin?

In cases where the infection does not seem to be responding to treatment, the provider may order follow-up laboratory tests. These microbiological studies, such as fungal cultures or KOH smears, can be repeated to monitor the patient's response and confirm that the original infection is still present.


Q: Is a metallic or unpleasant taste in the mouth a common side effect of Nistatin suspension?

While not always listed among the most common adverse events, some clinical data summaries and reports mention that a change in taste, sometimes described as a metallic taste, may be a possible side effect of the oral suspension.


Q: Why is Nistatin sometimes used in combination with other ingredients like steroids in topical creams?

Combination topical products that contain Nistatin and another ingredient, such as a corticosteroid, are available. The Nistatin treats the fungal infection, while the added corticosteroid is included to help reduce associated symptoms like inflammation, redness, and itching at the application site.


Q: What is the difference between Nistatin cream and Nistatin ointment?

Official patient information acknowledges various topical forms, including creams and ointments. Ointments are generally heavier and more occlusive than creams, and may be preferred for very dry or scaly skin. Conversely, the powder formulation is sometimes recommended for lesions that are very moist.

How should Nistatin be stored and disposed of?

How to Store and Dispose of Nystatin

The storage conditions for Nystatin are strictly defined by regulatory labeling to maintain the product's stability.


Storage Requirements

Nystatin products must generally be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted ranges up to 30 C (86 F). The medicine must be protected from light and it is required to avoid freezing the product, which is especially important for the suspension and cream forms.

The container must be kept tightly closed, and the oral suspension must not be used beyond 30 days after opening. All forms of Nystatin must be stored out of the reach and sight of children.


Disposal

Any unused or expired Nystatin must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nistatin found in:

A-Z Index: